Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Cash and Equivalents of $251.3 thousand for fiscal year 2025.
PROVECTUS BIOPHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $251.3K | -18.3% |
| 2024 | $307.4K | +301.5% |
| 2023 | $76.6K | +254.4% |
| 2022 | $21.6K | -96.8% |
| 2021 | $683.0K | +602.4% |
| 2020 | $97.2K | -83.5% |
| 2019 | $590.7K | +1058.6% |
| 2018 | $51.0K | -51.7% |
| 2017 | $105.5K | -90.9% |
| 2016 | $1.17M | -91.8% |
| 2015 | $14.18M | -18.5% |
| 2014 | $17.39M | +10.8% |
| 2013 | $15.70M | +1184.8% |
| 2012 | $1.22M | -84.1% |
| 2011 | $7.71M | -4.7% |
| 2010 | $8.09M | +149.8% |
| 2009 | $3.24M | +15.8% |
| 2008 | $2.80M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $72.5K | -61.3% | -81.2% |
| June 30, 2025 | $385.9K | +1204.7% | -1.2% |
| March 31, 2025 | $390.4K | +2064.9% | +108.3% |
| September 30, 2024 | $187.5K | -49.0% | +533.7% |
| June 30, 2024 | $29.6K | -83.2% | +64.0% |
| March 31, 2024 | $18.0K | -47.2% | -95.1% |
| September 30, 2023 | $367.2K | +447.9% | +108.7% |
| June 30, 2023 | $176.0K | +108.9% | +415.4% |
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -18.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, PROVECTUS BIOPHARMACEUTICALS, INC.’s cash and equivalents has declined by 91.0% (from $2.80 million to $251.3 thousand).
- The most recent figure is from PROVECTUS BIOPHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: